Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure

Completed

• Conditions: Heart Diseases

• Registration Number: NCT03232671
• Lead Sponsor: University Hospital, Essen

Brief Summary

Evaluating the additional value of Macrophage Migration Inhibitory factor (MIF) in cardiovascular diseases when assessed in clinical routine.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03
• Study First Submitted: 2017-07-25
• Study First Submitted QC: 2017-07-25
• Study First Posted: 2017-07-28
• Primary Completion: 2020-04
• Study Completion: 2020-09-01
• Status Verified: 2022-11
• Last Update Submitted: 2022-11-03
• Last Update Posted: 2022-11-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

All patients presenting with symptoms of heart failure to the West-German Heart and Vascular Center according to the definition of the ESC 2016.

• Patients fulfilling criteria for the diagnosis of HFrEF
• Patients fulfilling criteria for the diagnosis of HFpEF
• Patients fulfilling criteria for the diagnosis of HFmrEF
• Patients presenting with dyspnea according to the NYHA classification I-IV, elevated BNP/NT-proBNP levels and echocardiographic findings of heart failure.

Exclusion Criteria

• Age < 18 years
• Patients with symptoms of heart failure without fulfilling the criteria of the ESC guidelines 2016
• Denial to participate

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
180 days mortality	180 days

Trial Locations

Locations (1)

University Hospital of Essen; 🇩🇪 Essen, NRW, Germany